Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy

Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied. This study evaluates the treatment and molecular mechanisms of SD against TIA. The effective components and action targets...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical biology 2022-12, Vol.60 (1), p.1224-1236
Main Authors: Li, Xiangsheng, Li, Hui, Wang, Tingting, Zhao, Yang, Shao, Yuxin, Sun, Yizhao, Zhang, Yanfen, Liu, Zhongcheng
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
allergic targets
Allergies
Arthritis
Calcium signalling
cell degranulation
Chinese medicine
Degranulation
Genes
IgE
Immunoglobulin E
Lyn protein
MAP kinase
Mast cells
Molecular modelling
Pharmaceuticals
Pharmacology
Research methodology
Science
Signal transduction
Syk protein
Traditional Chinese medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3
cites cdi_FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3
container_end_page 1236
container_issue 1
container_start_page 1224
container_title Pharmaceutical biology
container_volume 60
creator Li, Xiangsheng
Li, Hui
Wang, Tingting
Zhao, Yang
Shao, Yuxin
Sun, Yizhao
Zhang, Yanfen
Liu, Zhongcheng
description Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied. This study evaluates the treatment and molecular mechanisms of SD against TIA. The effective components and action targets of SD were screened using TCMSP database, and allergy-related targets of SD were predicted using GeneCards and OMIM database. The obtained target intersections were imported into David database for GO analysis, and used R software to perform KEGG analysis. The RBL-2H3 cells sensitised by DNP-IgE/DNP-BSA were treated with different concentrations of SD (root decoction, 0.5, 1, and 2 mg/mL), prim-O-glucosylcimifugin (POG, 10, 40, and 80 μg/mL) and the positive control drug-ketotifen fumarate (KF, 30 μM) for 12 h, then subjected to cell degranulation and qPCR analysis. Eighteen active compounds of SD and 38 intersection targets were obtained: TIA-related signal pathways mainly include calcium signal pathway, PI3K-Akt signal pathway and MAPK signal pathway. Taking the β-Hex release rate of the model group as the base, the release rate of SD and POG in high dose groups were 43.79% and 57.01%, respectively, which were significantly lower than model group (p 
doi_str_mv 10.1080/13880209.2022.2086583
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2761422149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b4169a2a47864acdb7aa9c8b833896eb</doaj_id><sourcerecordid>2761422149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3</originalsourceid><addsrcrecordid>eNp9ksuO1DAQRSMEYoaBT0CKxIZNBr_i2BsEGvFoaQQLYG1VnEq3Z5y4sd2N8ve4HyANCza2VT51VaV7q-olJdeUKPKGcqUII_qaEcbKoWSr-KPqknZCNC2l8nF5F6Y5QBfVs5TuCCEt5-3T6oK3nSSt7C6r_AXzrxDv6-0G4gQ2-LBemh4SDjXM4JfkUh3GOm-wntBuYHZpOhS-wTakzezuw95BPbg9RGchQz2GeKRzRMgTzvnYvmyxXtXgPcb18rx6MoJP-OJ8X1U_Pn74fvO5uf36aXXz_raxLde5GZXgrUYF1mLHteL9UDYCLjQAR0RKOfB-BC1U37U9tVJRZbnETuEwqoFfVauT7hDgzmyjmyAuJoAzx0KIawMxO-vR9IJKDQxEp6QAO_QdgLaqV5wrLbEvWm9PWttdP-Fgy2IR_APRhz-z25h12BvNhGScFoHXZ4EYfu4wZTO5ZNF7mDHskmGH6SnjmhT01T_oXdjF4kahOkkFY1ToQrUnysaQUsTx7zCUmENGzJ-MmENGzDkjpe_dqc_NxasJiv1-MBkWH-IYYbYuGf5_id-rgcPq</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2761422149</pqid></control><display><type>article</type><title>Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Li, Xiangsheng ; Li, Hui ; Wang, Tingting ; Zhao, Yang ; Shao, Yuxin ; Sun, Yizhao ; Zhang, Yanfen ; Liu, Zhongcheng</creator><creatorcontrib>Li, Xiangsheng ; Li, Hui ; Wang, Tingting ; Zhao, Yang ; Shao, Yuxin ; Sun, Yizhao ; Zhang, Yanfen ; Liu, Zhongcheng</creatorcontrib><description>Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied. This study evaluates the treatment and molecular mechanisms of SD against TIA. The effective components and action targets of SD were screened using TCMSP database, and allergy-related targets of SD were predicted using GeneCards and OMIM database. The obtained target intersections were imported into David database for GO analysis, and used R software to perform KEGG analysis. The RBL-2H3 cells sensitised by DNP-IgE/DNP-BSA were treated with different concentrations of SD (root decoction, 0.5, 1, and 2 mg/mL), prim-O-glucosylcimifugin (POG, 10, 40, and 80 μg/mL) and the positive control drug-ketotifen fumarate (KF, 30 μM) for 12 h, then subjected to cell degranulation and qPCR analysis. Eighteen active compounds of SD and 38 intersection targets were obtained: TIA-related signal pathways mainly include calcium signal pathway, PI3K-Akt signal pathway and MAPK signal pathway. Taking the β-Hex release rate of the model group as the base, the release rate of SD and POG in high dose groups were 43.79% and 57.01%, respectively, which were significantly lower than model group (p &lt; 0.01), and significantly lower than KF group (63.83%, p &lt; 0.01, p &lt; 0.05). SD and POG could down-regulate the expression of related proteins in the Lyn/Syk, PI3K/AKT and MAPK signalling pathways. Saposhnikovia divaricata could inhibit IgE-induced degranulation of mast cells, providing a scientific basis for further research and clinical applications of SD in TIA treatment.</description><identifier>ISSN: 1388-0209</identifier><identifier>EISSN: 1744-5116</identifier><identifier>DOI: 10.1080/13880209.2022.2086583</identifier><identifier>PMID: 35760567</identifier><language>eng</language><publisher>Abingdon: Taylor &amp; Francis</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; allergic targets ; Allergies ; Arthritis ; Calcium signalling ; cell degranulation ; Chinese medicine ; Degranulation ; Genes ; IgE ; Immunoglobulin E ; Lyn protein ; MAP kinase ; Mast cells ; Molecular modelling ; Pharmaceuticals ; Pharmacology ; Research methodology ; Science ; Signal transduction ; Syk protein ; Traditional Chinese medicine</subject><ispartof>Pharmaceutical biology, 2022-12, Vol.60 (1), p.1224-1236</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3</citedby><cites>FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246231/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2761422149?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27501,27923,27924,37011,37012,44589,53790,53792,59142,59143</link.rule.ids></links><search><creatorcontrib>Li, Xiangsheng</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Wang, Tingting</creatorcontrib><creatorcontrib>Zhao, Yang</creatorcontrib><creatorcontrib>Shao, Yuxin</creatorcontrib><creatorcontrib>Sun, Yizhao</creatorcontrib><creatorcontrib>Zhang, Yanfen</creatorcontrib><creatorcontrib>Liu, Zhongcheng</creatorcontrib><title>Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy</title><title>Pharmaceutical biology</title><description>Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied. This study evaluates the treatment and molecular mechanisms of SD against TIA. The effective components and action targets of SD were screened using TCMSP database, and allergy-related targets of SD were predicted using GeneCards and OMIM database. The obtained target intersections were imported into David database for GO analysis, and used R software to perform KEGG analysis. The RBL-2H3 cells sensitised by DNP-IgE/DNP-BSA were treated with different concentrations of SD (root decoction, 0.5, 1, and 2 mg/mL), prim-O-glucosylcimifugin (POG, 10, 40, and 80 μg/mL) and the positive control drug-ketotifen fumarate (KF, 30 μM) for 12 h, then subjected to cell degranulation and qPCR analysis. Eighteen active compounds of SD and 38 intersection targets were obtained: TIA-related signal pathways mainly include calcium signal pathway, PI3K-Akt signal pathway and MAPK signal pathway. Taking the β-Hex release rate of the model group as the base, the release rate of SD and POG in high dose groups were 43.79% and 57.01%, respectively, which were significantly lower than model group (p &lt; 0.01), and significantly lower than KF group (63.83%, p &lt; 0.01, p &lt; 0.05). SD and POG could down-regulate the expression of related proteins in the Lyn/Syk, PI3K/AKT and MAPK signalling pathways. Saposhnikovia divaricata could inhibit IgE-induced degranulation of mast cells, providing a scientific basis for further research and clinical applications of SD in TIA treatment.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>allergic targets</subject><subject>Allergies</subject><subject>Arthritis</subject><subject>Calcium signalling</subject><subject>cell degranulation</subject><subject>Chinese medicine</subject><subject>Degranulation</subject><subject>Genes</subject><subject>IgE</subject><subject>Immunoglobulin E</subject><subject>Lyn protein</subject><subject>MAP kinase</subject><subject>Mast cells</subject><subject>Molecular modelling</subject><subject>Pharmaceuticals</subject><subject>Pharmacology</subject><subject>Research methodology</subject><subject>Science</subject><subject>Signal transduction</subject><subject>Syk protein</subject><subject>Traditional Chinese medicine</subject><issn>1388-0209</issn><issn>1744-5116</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ksuO1DAQRSMEYoaBT0CKxIZNBr_i2BsEGvFoaQQLYG1VnEq3Z5y4sd2N8ve4HyANCza2VT51VaV7q-olJdeUKPKGcqUII_qaEcbKoWSr-KPqknZCNC2l8nF5F6Y5QBfVs5TuCCEt5-3T6oK3nSSt7C6r_AXzrxDv6-0G4gQ2-LBemh4SDjXM4JfkUh3GOm-wntBuYHZpOhS-wTakzezuw95BPbg9RGchQz2GeKRzRMgTzvnYvmyxXtXgPcb18rx6MoJP-OJ8X1U_Pn74fvO5uf36aXXz_raxLde5GZXgrUYF1mLHteL9UDYCLjQAR0RKOfB-BC1U37U9tVJRZbnETuEwqoFfVauT7hDgzmyjmyAuJoAzx0KIawMxO-vR9IJKDQxEp6QAO_QdgLaqV5wrLbEvWm9PWttdP-Fgy2IR_APRhz-z25h12BvNhGScFoHXZ4EYfu4wZTO5ZNF7mDHskmGH6SnjmhT01T_oXdjF4kahOkkFY1ToQrUnysaQUsTx7zCUmENGzJ-MmENGzDkjpe_dqc_NxasJiv1-MBkWH-IYYbYuGf5_id-rgcPq</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Li, Xiangsheng</creator><creator>Li, Hui</creator><creator>Wang, Tingting</creator><creator>Zhao, Yang</creator><creator>Shao, Yuxin</creator><creator>Sun, Yizhao</creator><creator>Zhang, Yanfen</creator><creator>Liu, Zhongcheng</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221231</creationdate><title>Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy</title><author>Li, Xiangsheng ; Li, Hui ; Wang, Tingting ; Zhao, Yang ; Shao, Yuxin ; Sun, Yizhao ; Zhang, Yanfen ; Liu, Zhongcheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>allergic targets</topic><topic>Allergies</topic><topic>Arthritis</topic><topic>Calcium signalling</topic><topic>cell degranulation</topic><topic>Chinese medicine</topic><topic>Degranulation</topic><topic>Genes</topic><topic>IgE</topic><topic>Immunoglobulin E</topic><topic>Lyn protein</topic><topic>MAP kinase</topic><topic>Mast cells</topic><topic>Molecular modelling</topic><topic>Pharmaceuticals</topic><topic>Pharmacology</topic><topic>Research methodology</topic><topic>Science</topic><topic>Signal transduction</topic><topic>Syk protein</topic><topic>Traditional Chinese medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xiangsheng</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Wang, Tingting</creatorcontrib><creatorcontrib>Zhao, Yang</creatorcontrib><creatorcontrib>Shao, Yuxin</creatorcontrib><creatorcontrib>Sun, Yizhao</creatorcontrib><creatorcontrib>Zhang, Yanfen</creatorcontrib><creatorcontrib>Liu, Zhongcheng</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xiangsheng</au><au>Li, Hui</au><au>Wang, Tingting</au><au>Zhao, Yang</au><au>Shao, Yuxin</au><au>Sun, Yizhao</au><au>Zhang, Yanfen</au><au>Liu, Zhongcheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy</atitle><jtitle>Pharmaceutical biology</jtitle><date>2022-12-31</date><risdate>2022</risdate><volume>60</volume><issue>1</issue><spage>1224</spage><epage>1236</epage><pages>1224-1236</pages><issn>1388-0209</issn><eissn>1744-5116</eissn><abstract>Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied. This study evaluates the treatment and molecular mechanisms of SD against TIA. The effective components and action targets of SD were screened using TCMSP database, and allergy-related targets of SD were predicted using GeneCards and OMIM database. The obtained target intersections were imported into David database for GO analysis, and used R software to perform KEGG analysis. The RBL-2H3 cells sensitised by DNP-IgE/DNP-BSA were treated with different concentrations of SD (root decoction, 0.5, 1, and 2 mg/mL), prim-O-glucosylcimifugin (POG, 10, 40, and 80 μg/mL) and the positive control drug-ketotifen fumarate (KF, 30 μM) for 12 h, then subjected to cell degranulation and qPCR analysis. Eighteen active compounds of SD and 38 intersection targets were obtained: TIA-related signal pathways mainly include calcium signal pathway, PI3K-Akt signal pathway and MAPK signal pathway. Taking the β-Hex release rate of the model group as the base, the release rate of SD and POG in high dose groups were 43.79% and 57.01%, respectively, which were significantly lower than model group (p &lt; 0.01), and significantly lower than KF group (63.83%, p &lt; 0.01, p &lt; 0.05). SD and POG could down-regulate the expression of related proteins in the Lyn/Syk, PI3K/AKT and MAPK signalling pathways. Saposhnikovia divaricata could inhibit IgE-induced degranulation of mast cells, providing a scientific basis for further research and clinical applications of SD in TIA treatment.</abstract><cop>Abingdon</cop><pub>Taylor &amp; Francis</pub><pmid>35760567</pmid><doi>10.1080/13880209.2022.2086583</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1388-0209
ispartof Pharmaceutical biology, 2022-12, Vol.60 (1), p.1224-1236
issn 1388-0209
1744-5116
language eng
recordid cdi_proquest_journals_2761422149
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content Database
subjects 1-Phosphatidylinositol 3-kinase
AKT protein
allergic targets
Allergies
Arthritis
Calcium signalling
cell degranulation
Chinese medicine
Degranulation
Genes
IgE
Immunoglobulin E
Lyn protein
MAP kinase
Mast cells
Molecular modelling
Pharmaceuticals
Pharmacology
Research methodology
Science
Signal transduction
Syk protein
Traditional Chinese medicine
title Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Network%20pharmacology-based%20analysis%20of%20the%20mechanism%20of%20Saposhnikovia%20divaricata%20for%20the%20treatment%20of%20type%20I%20allergy&rft.jtitle=Pharmaceutical%20biology&rft.au=Li,%20Xiangsheng&rft.date=2022-12-31&rft.volume=60&rft.issue=1&rft.spage=1224&rft.epage=1236&rft.pages=1224-1236&rft.issn=1388-0209&rft.eissn=1744-5116&rft_id=info:doi/10.1080/13880209.2022.2086583&rft_dat=%3Cproquest_pubme%3E2761422149%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c539t-f84359e8acce73983bd138a349aa3eee113a3bfa948b75b1c6818c36e78edf8d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2761422149&rft_id=info:pmid/35760567&rfr_iscdi=true